Nuformix PLC (LSE:NFX) is developing a pre-clinical programme to further assess the potential of NXP004, a reformulation of AstraZeneca blockbuster cancer drug Lynparza.
The aim of the work is to come up with a version of the AZ product that is both bioequivalent and 'bio-better' than the existing treatment.
Lynparza, also known as olaparib, has "significant challenges in achieving effective oral delivery".
Nuformix’s NXP004 cocrystals may help overcome these problems. In fact, work carried out previously points to their "enhanced performance" when compared with the current treatment.
So, researchers will shortly begin the production scale-up of its lead cocrystal.
The plan then is to directly compare the AZ product with the Nuformix formulation. Specifically, Nuformix wants to find out how well and quickly its drug turns from a solid into a liquid solution – a process that will assess its dissolution performance.
“Based on the results from these studies a formulation development programme may be initiated,” investors were told.
“The aims of this work will be to develop prototype formulations that offer the potential to be both bioequivalent and 'bio-better' versus the Lynparza product.”
The AZ drug was developed to treat ovarian cancer, but since then its label has been broadened to include breast, prostate and pancreatic cancers.
Sales last year were US$2.7bn, but analysts expect the figure to be closer to US$10bn by 2028.
“We believe that NXP004 has considerable commercial potential and the work we are now undertaking is designed to formulate our lead co-crystals towards a product form suitable for human use,” said Dr Julian Gilbert, Nuformix’s non-executive director.
"The strategy of the group is to continue to optimise value from its existing assets while maintaining tight control of costs. This work will direct and support future out-licensing discussions for NXP004.”